Novye oral'nye antikoagulyanty v profilaktike i lechenii venoznykh trombozov i tromboemboliy: fokus na rivaroksaban


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents the main reasons for the development of venous thromboembolism and its complications, and describes the main risks of thrombosis. The results of studies forming the evidence base for the use of direct factor Xa inhibitor rivaroxaban for treatment of deep venous thrombosis, prevention of recurrent thrombosis, prevention of venous thromboembolism in patients undergoing orthopedic surgery and having atrial fibrillation, are discussed in detail.

全文:

受限制的访问

作者简介

M. Glezer

参考

  1. Hawkins D. The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism. Pharmacotherapy. 2004;24(10 Pt 2):179S-183S.
  2. Fitzmaurice D.A., Murray E. Thromboprophylaxis for adults in hospital. BMJ. 2007;334(7602): 1017-18.
  3. Go A.S., Hylek E. M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-75.
  4. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-e354.
  5. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):546S-592S.
  6. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-88.
  7. Kannel W.B., Benjamin E.J. Status of the epidemiology of atrial fibrillation. Med. Clin. North Am. 2008;92(1):17-40.
  8. Patel M.R., Mahaffey K.W., Garg J., et al. ROCKET AF Investigators.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011;365(10):883-91.
  9. Turpie A.G., Lassen M.R., Eriksson B.I., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost. 2011;105(3):444-53.
  10. Levitan B., Yuan Z., Turpie A.G., et al. Benefitrisk assessment of rivaroxaban versus enoxapa-rin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc. Health Risk Manag. 2014;10:157-67.
  11. Quinlan D.J., Eikelboom J.W., Dahl O.E., et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J. Thromb. Haemost. 2007;5(7):1438-43.
  12. EINSTEIN Investigators, Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 2010;363(26):2499-510.
  13. EINSTEIN-PE Investigators, Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 2012;366(14):1287-97.
  14. Prins M.H., Lensing A.W., Bauersachs R., et al. EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb. J. 2013;11 (1 ):21.
  15. Warwick D., Friedman R.J., Agnelli G., et ai. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J. Bone Joint. Surg. Br. 2007;89(6):799-807.
  16. Seagroatt V., Tan H.S., Goldacre M., et al. Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ. 1991 ;303(6815):1431 -35.
  17. Pellegrini V.D. Jr, Donaldson C.T., Färber D.C., et al. The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin. Orthop. Relat. Res. 2005;441:56-62.
  18. Bjornara B.T., Gudmundsen T.E., Dahl O.E. Frequency and timing of clinical venous thromboembolism after major joint surgery. J. Bone Joint. Surg. Br. 2006;88(3):386-91.
  19. Huisman M.V., Bounameaux H. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention. Semin. Vase. Med. 2005;5(3):276-84.
  20. Romuaidi E., Donadini M.P., Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev. Cardiovasc. Ther. 2011;9(7): 841-44.
  21. Bamber L., Wang M.Y., Prins M.H., et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb. Haemost. 2013;110(4):732-41.
  22. Kakkar A.Κ., Mueller I., Bassand J.P., et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am. Heart J. 2012;163(1 ):13-9.
  23. Kakkar A.Κ., Mueller I., Bassand J.P., et al. GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##